Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust,... Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 µg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

Download PDF

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

Fragapane, Elena; Gasparini, Roberto; Schioppa, Francesco; Laghi-Pasini, Franco; Montomoli, Emanuele; Banzhoff, Angelika
Clinical and Vaccine Immunology , Volume 17 (11): 1817 – Nov 1, 2010

Abstract

Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 µg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

Loading next page...
 
/lp/american-society-for-microbiology/a-heterologous-mf59-adjuvanted-h5n1-prepandemic-influenza-booster-x7hpuB19nd

References (12)

Publisher
American Society For Microbiology
Copyright
Copyright © 2010 by the American Society For Microbiology.
ISSN
1556-6811
eISSN
1556-6811
DOI
10.1128/CVI.00461-09
Publisher site
See Article on Publisher Site

Abstract

Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 µg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

Journal

Clinical and Vaccine Immunology – American Society For Microbiology

Published: Nov 1, 2010

There are no references for this article.